New Zealand firm Ora Pharm has struck a deal to supply dried flower to Canngea for the manufacture and distribution of its medicinal cannabis products on both sides of the Tasman.
The partnership marks Ora Pharm’s launch in the Australian market with both dried flower and finished products.
It said it is developing patient-ready tincture formulations blended with native New Zealand botanicals which will be manufactured by Canngea under strict GMP processes. It is also developing unique cannabis strains exclusively for its new partner.
Founder and CEO Zoe Reece said: “Pharmaceutical-grade cannabis quality starts with the seed, and the seed we are growing our cannabis from is a unique, high-quality, high-yield strain which we expect to produce excellent results.”
